You are here

Multiple Sclerosis Drug Plegridy (Peginterferon) Submitted for FDA Review

Treatment significantly reduces disease activity in phase III trial (May 21)

A biologics license application (BLA) has been submitted to the FDA for approval of Plegridy (peginterferon beta-1a; Biogen Idec), a pegylated subcutaneous injectable candidate for relapsing forms of multiple sclerosis (MS).

The regulatory submission was based on results from the first year of the 2-year phase III ADVANCE trial involving 1,516 patients with relapsing-remitting MS. In this study, Plegridy met all primary and secondary endpoints at 1 year by significantly reducing disease activity — including relapses, disability progression, and brain lesions — compared with placebo, and showed favorable safety and tolerability profiles.

Plegridy is a new molecular entity in which interferon (IFN) beta-1a is pegylated to extend its half-life and to prolong its exposure in the body. (Pegylation is the process of covalent attachment of polyethylene glycol [PEG] polymer chains to another molecule.) The drug is a member of the IFN class of treatments and, if approved, would be a new addition to this class, which is often used as a first-line therapy for MS.

The ADVANCE trial is investigating two dosing regimens of Plegridy — 125 mcg administered subcutaneously every 2 weeks or every 4 weeks — compared with placebo. The analysis for all primary and secondary efficacy endpoints occurred at 1 year. After the first year, patients receiving placebo were re-randomized to one of the Plegridy arms for the duration of the second year of the study. After completing 2 years in the ADVANCE trial, the patients will have the option of enrolling in an open-label extension study (ATTAIN) and will be followed for up to 4 years.

Source: Biogen Idec; May 21, 2013.

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs
Acasti reports disappointing results for a second Omega-3-based drug